PTC Therapeutics (PTCT) is advancing 8% after investment bank Cantor Fitzgerald’ hiked its price target on the drug maker’s ...

Cantor Fitzgerald's analysts demonstrated a positive outlook on PTC Therapeutics (NASDAQ:PTCT), increasing the price target to $113.00 from the previous $76.00. The firm maintains an Overweight rating ...

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on PTC Therapeutics (PTCT – Research Report) today and set a price target of ...

Cantor Fitzgerald raised the firm’s price target on PTC Therapeutics (PTCT) to $113 from $76 and keeps an Overweight rating on the shares. PTC ...

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Dr. Jerome Zeldis and Dr. Blythe Sather bring exceptional backgrounds in cell therapy and solid tumorsCAMBRIDGE, Mass., Jan.

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has earned a consensus rating of “Hold” from the fifteen research ...

Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for PTC Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the ...

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce today that Health Canada has authorized Vabysmo® ...

Sepiapterin is under clinical development by PTC Therapeutics and currently in Pre-Registration for Phenylketonuria (PKU). According to GlobalData, Pre-Registration drugs for Phenylketonuria (PKU) ...

Vatiquinone is under clinical development by PTC Therapeutics and currently in Phase III for Subacute Necrotizing Encephalomyelopathy (Leigh Disease). According to GlobalData, Phase III drugs for ...

Technology companies outperformed expectations, achieving solid revenue growth while expressing cautious optimism for the coming quarters. The healthcare sector showed strong performance, with stable ...